July 31, 2025

Guselkumab Improves Scalp Psoriasis in Patients With Skin of Color

This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.

Conexiant

July 29, 2025

Nonblistering Papules: Genetic Mystery Cracked

A woman with a decades-long history of intensely pruritic, nonblistering papules on her extremities was diagnosed with dystrophic epidermolysis bullosa pruriginosa, confirmed by COL7A1 gene sequencing, after a comprehensive clinicopathologic evaluation.

Conexiant

January 07, 2025

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

September 17, 2024

Can Hair Dye Cause Retinopathy?

Aromatic amines may cause long-term RPE dysfunction

Conexiant

July 31, 2024

Alopecia Areata Linked to Mental, Autoimmune Risks

New study published in JAMA Dermatology reveals that patients newly diagnosed with alopecia areata face a higher risk of developing psychiatric and autoimmune disorders.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant

November 26, 2024

Do Cancer Drugs Trigger Skin Issues?

A recent analysis reveals that nearly 50% of significant dermatologic adverse events linked to anticancer therapies are associated with targeted therapies, with rash, dry skin, and alopecia being the most commonly reported adverse events.

Conexiant